Ng P Y, Allan R N, Hofmann A F
J Lipid Res. 1977 Nov;18(6):753-8.
Studies were carried out to assess the stability of the label in [11,12-(3)H(2)]chenodeoxycholic acid and [11,12-(3)H(2)]lithocholic acid during enterohepatic cycling and thus define the suitability of these tracers for isotope dilution studies of bile acids in man. To do this, [11,12-(3)H(2)]-chenodeoxycholic acid and [24-(14)C]chenodeoxycholic acid were administered simultaneously to six healthy adults. The (3)H/(14)C ratio of biliary chenodeoxycholic acid and the specific activity of biliary chenodeoxycholic acid were determined to permit calculation of pool size and turnover rate by the conventional isotope dilution procedure of Lindstedt (1957. Acta Physiol. Scand. 40: 1). Excretion of label in urine was measured as well as the (3)H/(14)C ratio of fecal bile acids. Similar studies were carried out with [11,12-(3)H(2)]lithocholic acid and [24-(14)C]lithocholic acid. With [11,12-(3)H(2)]chenodeoxycholic acid, 10-15% of the label was lost during the first 24 hours, after which the (3)H/(14)C ratio of biliary chenodeoxycholic acid remained constant. The loss of (3)H caused a consistent overestimate of pool size by 10-15%, but since the fractional turnover rate of the two isotopes was identical, the calculated rate of synthesis was 10-15% greater when determined using (3)H. The loss of (3)H was attributed to the presence of (3)H in positions other than 11 and 12 occurring during the labeling procedure when the unsaturated precursor was exposed to carrier-free tritium gas. The (3)H/(14)C ratio of feces was consistently below that of bile, suggesting bacterial removal of additional (3)H during distal intestinal passage. In contrast, [11,12-(3)H(2)]lithocholic acid lost (3)H continuously, so that by 2 days after administration, the (3)H/(14)C ratio had fallen to nearly half of that of the administered mixture. It is concluded that isotope dilution studies may be carried out with one preparation of [11,12-(3)H(2)]chenodeoxycholic acid with an error of 10-15%; possibly a more stable preparation can be prepared with a gentler tritiation procedure. One preparation of [11,12-(3)H(2)]lithocholic acid was unsatisfactory for isotope dilution studies in man.
开展了多项研究,以评估[11,12-(3)H(2)]鹅去氧胆酸和[11,12-(3)H(2)]石胆酸在肠肝循环过程中标记物的稳定性,从而确定这些示踪剂是否适合用于人体胆汁酸的同位素稀释研究。为此,同时向6名健康成年人施用了[11,12-(3)H(2)]-鹅去氧胆酸和[24-(14)C]鹅去氧胆酸。测定胆汁中鹅去氧胆酸的(3)H/(14)C比值和胆汁中鹅去氧胆酸的比活度,以便通过Lindstedt(1957年,《生理学杂志》,40:1)的传统同位素稀释程序计算池大小和周转率。测量尿液中标记物的排泄以及粪便胆汁酸的(3)H/(14)C比值。对[11,12-(3)H(2)]石胆酸和[24-(14)C]石胆酸进行了类似研究。使用[11,12-(3)H(2)]鹅去氧胆酸时,在最初24小时内10 - 15%的标记物丢失,此后胆汁中鹅去氧胆酸的(3)H/(14)C比值保持恒定。(3)H的丢失导致池大小一直被高估10 - 15%,但由于两种同位素的分数周转率相同,使用(3)H测定时计算出的合成速率高10 - 15%。(3)H的丢失归因于标记过程中当不饱和前体暴露于无载体氚气时,11和12位以外的位置存在(3)H。粪便的(3)H/(14)C比值一直低于胆汁的比值,表明在远端肠道通过过程中细菌去除了额外的(3)H。相比之下,[11,12-(3)H(2)]石胆酸持续丢失(3)H,因此在给药后2天,(3)H/(14)C比值降至给药混合物比值的近一半。结论是,使用一种[11,12-(3)H(2)]鹅去氧胆酸制剂进行同位素稀释研究时误差为10 - 15%;可能通过更温和的氚化程序可以制备出更稳定的制剂。一种[11,12-(3)H(2)]石胆酸制剂不适合用于人体同位素稀释研究。